IMU Biosciences has raised $53 million in a Series A financing round, pledging to use the funds to change understanding, diagnosis and treatment of disease.

The biotechnology company has built what it claims to be the world’s largest immune dataset, scaling to more than 25,000 individuals in 2026 through access to patient samples and population wide clinical data.

By combining high-fidelity multi-omic analysis with proprietary machine learning analytics, IMU can use a simple blood sample to measure over 100 million immune data points, creating a detailed immune picture.

IMU says it has raised $60 million to date and will use the funds to deliver its vision to change how we understand, diagnose and treat disease. The proceeds from the Series A financing round will support the company’s operational expansion and clinical platform and infrastructure development.

IMU says the funding will also be used to advance its clinical programmes, including its Stem Cell Transplant and Solid Organ Transplant Programmes as well as MANIFEST, a UK research consortium investigating patient response to cancer immunotherapies.

“We are delighted to announce IMU’s fundraise, which will allow us to expand our operations and develop our platform whilst continuing to deploy our groundbreaking technology across our clinical programmes as we work to fundamentally change how we understand, diagnose, and treat disease,” said Dr John Baker, Chief Executive Officer of IMU Biosciences.

“Despite the immune system’s profound importance on all aspects of our health, the system as a whole remains poorly understood – obscured by tools that are fragmented, mechanistic and low-resolution.

“With the largest immune system dataset globally and proprietary technology, IMU is uniquely positioned to fuel discoveries, devise treatments and empower clinicians; improving outcomes for patients across the full spectrum of human health and disease.”

The post IMU Biosciences raises $53m to expand disease platform appeared first on Drug Discovery World (DDW).